Heavy Metal Chelation in Neurotoxic Exposures

Neurologic Clinics

Volumn 29, Issue 3, 2011, Pages 607-622

  Jang, David H ^a   Hoffman, Robert S ^a  

^a BELLEVUE HOSPITAL CENTER   (United States)

Author keywords

Chelation; Heavy metals; Neurotoxic; Postchelation challenge

Indexed keywords

ACTINIDE; ALUMINUM; ARSENIC; CADMIUM; COPPER; DIMERCAPROL; EDETATE CALCIUM DISODIUM; EDETIC ACID; FERRIC FERROCYANIDE; IRON; LANTHANIDE; MERCURY; METALLOID; METHYLMERCURY; PENICILLAMINE; PLACEBO; SILVER CHLORIDE; SUCCIMER; THALLIUM; VINYL CHLORIDE; ZINC;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ACUTE LUNG INJURY; AGRANULOCYTOSIS; ALOPECIA; ANEMIA; ANOREXIA; ANOSMIA; APLASIA; APLASTIC ANEMIA; ARSENIC POISONING; ATOM; BIOACCUMULATION; BRAIN DISEASE; BRAIN EDEMA; BURN; CARDIOMYOPATHY; CESIUM POISONING; CHELATION THERAPY; CHEMOSIS; CHILL; CONJUNCTIVA DISEASE; CONSTIPATION; CONTACT DERMATITIS; COPPER POISONING; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG HYPERSENSITIVITY; DRUG INTOXICATION; ELECTRIC CONDUCTIVITY; FATIGUE; FECES; FEVER; GOITER; GONORRHEA; GRANULOCYTOPENIA; GRAVITY; HEADACHE; HEMOLYSIS; HEMORRHAGIC GASTRITIS; HUMAN; HYPERPLASIA; HYPERREFLEXIA; HYPERTENSION; HYPOCALCEMIA; HYPOTENSION; INJECTION SITE ABSCESS; INJECTION SITE PAIN; INTOXICATION; KIDNEY DISEASE; KIDNEY FAILURE; LACRIMATION; LEAD ENCEPHALOPATHY; LEAD POISONING; LIVER TOXICITY; LUNG FIBROSIS; MALAISE; MERCURIALISM; METALLIC TASTE; MUCOSA INFLAMMATION; MYALGIA; MYELODYSPLASTIC SYNDROME; MYOCARDITIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; NOSE CONGESTION; OCCUPATIONAL ASTHMA; OPTIC NERVE DISEASE; OSTEOMALACIA; PANCYTOPENIA; PAPULE; PARKINSONISM; PERIPHERAL NEUROPATHY; PNEUMOCONIOSIS; PNEUMONIA; POLYCYTHEMIA; PRIORITY JOURNAL; PROTHROMBIN TIME; PUSTULE; QT PROLONGATION; RASH; REVIEW; RHINORRHEA; SALIVATION; SIDE EFFECT; SIDEROBLASTIC ANEMIA; SKIN DISCOLORATION; SNEEZING; STOMACH LAVAGE; STOOL COLOR; TACHYCARDIA; TASTE AVERSION; THALLIUM INTOXICATION; THERMAL CONDUCTIVITY; TORSADE DES POINTES; ULCER; URINALYSIS; VOMITING;

CHELATING AGENTS; CHELATION THERAPY; HUMANS; METALS, HEAVY; NEUROTOXICITY SYNDROMES;

EID: 79960820110     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2011.05.002     Document Type: Review

References (85)

1. Duffus J.H. "Heavy metals" a meaningless term? (IUPAC Technical Report). Pure Appl Chem 2002, 74:793-807.
2. Gaslin M.T., Rubin C., Pribitkin E.A. Silver nasal sprays: misleading Internet marketing. Ear Nose Throat J 2008, 87:217-220.
3. Hori K., Martin T.G., Rainey P., et al. Believe it or not silver still poisons!. Vet Hum Toxicol 2002, 44:291-292.
4. Griffin J.P. Famous names: the Esing Bakery, Hong Kong. Adverse Drug React Toxicol Rev 1997, 16:79-81.
5. Meggs W.J., Hoffman R.S., Shih R.D., et al. Thallium poisoning from maliciously contaminated food. J Toxicol Clin Toxicol 1994, 32:723-730.
6. Desenclos J.C., Wilder M.H., Coppenger G.W., et al. Thallium poisoning: an outbreak in Florida, 1988. South Med J 1992, 85:1203-1206.
7. Powell P.P. Minamata disease: a story of mercury's malevolence. South Med J 1991, 84:1352-1358.
8. Ahsan H., Chen Y., Parvez F., et al. Arsenic exposure from drinking water and risk of premalignant skin lesions in Bangladesh: baseline results from the health effects of arsenic longitudinal study. Am J Epidemiol 2006, 163:1138-1148.
9. Patwardhan J.R., Finckh E.S. Fatal cadmium-fume pneumonitis. Med J Aust 1976, 1:962-966.
10. Clarkson T.W., Magos L., Myers G.J. The toxicology of mercury-current exposures and clinical manifestations. N Engl J Med 2003, 349:1731-1737.
11. Schultz S.T. Does thimerosal or other mercury exposure increase the risk for autism? A review of current literature. Acta Neurobiol Exp (Wars) 2010, 70:187-195.
12. Poland G.A., Spier R. Fear, misinformation, and innumerates: how the Wakefield paper, the press, and advocacy groups damaged the public health. Vaccine 2010, 28:2361-2362.
13. Schaffer A.W., Pilger A., Engelhardt C., et al. Increased blood cobalt and chromium after total hip replacement. J Toxicol Clin Toxicol 1999, 37:839-844.
14. Steens W., von Foerster G., Katzer A. Severe cobalt poisoning with loss of sight after ceramic-metal pairing in a hip-a case report. Acta Orthop 2006, 77:830-832.
15. Jacobs J.J., Skipor A.K., Patterson L.M., et al. Metal release in patients who have had a primary total hip arthroplasty. A prospective controlled, longitudinal study. J Bone Joint Surg Am 1998, 80:1447-1448.
16. Savory J., Sedor F.A. Arsenic poisoning. Clinical chemistry and chemical toxicology of metals 1977, 271-286. Elsevier/North-Holland, New York. S.S. Brown (Ed.).
17. Krachler M., Zheng J., Emons H. Speciation of antimony for the 21st century: promises and pitfalls. Trends Anal Chem 2001, 20:79-90.
18. Lidsky T.I., Schneider J.S. Lead neurotoxicity in children: basic mechanisms and clinical correlates. Brain 2003, 126:5-19.
19. Regan C.M. Neural cell adhesion molecules, neuronal development and lead toxicity. Neurotoxicology 1993, 14:69-74.
20. Melnick R.L., Monti L.G., Motzkin S.M. Uncoupling of mitochondrial oxidative phosphorylation by thallium. Biochem Biophys Res Commun 1976, 69:68-73.
21. Mullins L.J., Moore R.D. The movement of thallium ions in muscle. J Gen Physiol 1960, 43:759-773.
22. Ibrahim D., Froberg B., Wolf A., et al. Heavy metal poisoning: clinical presentations and pathophysiology. Clin Lab Med 2006, 26:67-97.
23. Josephs K.A., Ahlskog J.E., Klos K.J., et al. Neurologic manifestations in welders with pallidal MRI T1 hyperintensity. Neurology 2005, 64:2033-2039.
24. Stepens A., Logina I., Liguts V., et al. A parkinsonian syndrome in methcathinone users and the role of manganese. N Engl J Med 2008, 358:1009-1017.
25. Short A.I., Winney R.J., Robson J.S. Reversible microcytic hypochromic anaemia in dialysis patients due to aluminum intoxication. Proc Eur Dial Transplant Assoc 1980, 17:226-233.
26. Smith E.C., Mahurkar S.D., Mamdani B.H., et al. Diagnosing dialysis dementia. Dial Transplant 1978, 7:1264-1274.
27. Mendelowitz P.C., Hoffman R.S., Weber S. Bismuth absorption and myoclonic encephalopathy during bismuth subsalicylate therapy. Ann Intern Med 1990, 112:140-141.
28. Monseu G., Struelens M., Roland M. Bismuth encephalopathy. Acta Neurol Belg 1976, 76:301-308.
29. Heyman A., Pfeiffer J.B., Willett R.W. Peripheral neuropathy caused by arsenical intoxication: a study of 41 cases with observations on the effects of BAL (2,3-dimercaptopropanol). N Engl J Med 1956, 254:401-409.
30. Chuttani P.N., Chawla L.S., Sharma T.D. Arsenical neuropathy. Neurology 1967, 17:269-274.
31. Bank W.J., Pleasure D.E., Suzuki K., et al. Thallium poisoning. Arch Neurol 1972, 26:456-464.
32. Arbouine M.W., Wilson H.K. The effect of seafood consumption on the assessment of occupational exposure to arsenic by urinary arsenic speciation measurements. J Trace Elem Electrolytes Health Dis 1992, 6:153-160.
33. Brown M.J., Willis T., Omalu B., et al. Deaths resulting from hypocalcemia after administration of edetate disodium: 2003-2005. Pediatrics 2006, 118:e534-e536.
34. Nagaraj M.V., Rao P.V., Susarala S. Copper sulphate poisoning, hemolysis and methaemoglobinemia. J Assoc Physicians India 1985, 33:308-309.
35. Barbey J.T., Pezzullo J.C., Soignet S.L. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 2003, 21:3609-3615.
36. Beckman K.J., Bauman J.L., Pimental P.A., et al. Arsenic-induced torsade de pointes. Crit Care Med 1991, 19:290-292.
37. Ortega-Carnicer J., Alcázar R., De la Torre M., et al. Pentavalent antimonial-induced torsade de pointes. J Electrocardiol 1997, 30:143-145.
38. Greenberg G.N., Levine R.J. Urinary creatinine excretion is not stable: a new method for assessing urinary toxic substance concentrations. J Occup Med 1989 Oct, 31:832-838.
39. Sata F., Araki S., Yokoyama K., et al. Adjustment of creatinine-adjusted values in urine to urinary flow rate: a study of eleven heavy metals and organic substances. Int Arch Occup Environ Health 1995, 68:64-68.
40. Wagner S.L., Weswig P. Arsenic in blood and urine of forest workers as indices of exposure to cacodylic acid. Arch Environ Health 1974, 28:77-79.
41. Kersjes M.P., Maurer J.R., Trestrail J.H., et al. An analysis of arsenic exposures referred to the Blodgett Regional Poison Center. Vet Hum Toxicol 1987, 29:75-78.
42. Barrett S. Commercial hair analysis. Science or scam?. JAMA 1985, 254(8):1041-1045.
43. Cullen N.M., Wolf L.R., St Clair D. Pediatric arsenic ingestion. Am J Emerg Med 1995, 13:432-435.
44. Barnhart S, Rosenstock L. Cadmium chemical pneumonitis chest 1984;789-91.
45. Czerwinski A.W., Ginn H.E. Bismuth nephrotoxicity. Am J Med 1964, 37:969-975.
46. Reed D., Crawley J., Faro S.N., et al. Thallotoxicosis. Acute manifestations and sequelae. JAMA 1963, 183:516-522.
47. Goebel H.H., Schmidt P.F., Bohl J., et al. Polyneuropathy due to acute arsenic intoxication: biopsy studies. J Neuropathol Exp Neurol 1990, 49:137-149.
48. Le Quesne P.M., McLeod J.G. Peripheral neuropathy following a single exposure to arsenic: clinical course in four patients with electrophysiological and histological studies. J Neurol Sci 1977, 32:437-451.
49. Cersosimo M.G., Koller W. The diagnosis of manganese-induced parkinsonism. Neurotoxicology 2006, 27(3):340-346.
50. Arjona A., Mata M., Bonet M. Diagnosis of chronic manganese intoxication by magnetic resonance imaging. N Engl J Med 1997, 336:964-965.
51. Needleman H.L., Gunnoe C., Leviton A., et al. Deficits in psychological and classroom performance of children with elevated dentine lead levels. N Engl J Med 1979, 300:689-695.
52. Young E.G., Smith R.P. Arsenic content of hair and bone in acute and chronic arsenical poisoning: review of 2 cases examined posthumously from medico-legal aspect. Br Med J 1942, 1:251-253.
53. Rosenman K.D., Valciukas J.A., Glickman L., et al. Sensitive indicators of inorganic mercury toxicity. Arch Environ Health 1986, 41:208-215.
54. Whitaker J.A., Austin W., Nelson J.D. Edathamil calcium disodium (Versenate) diagnostic test for lead poisoning. Pediatrics 1962, 29:384-388.
55. Weinberger H.L., Post E.M., Schneider T., et al. An analysis of 248 initial mobilization tests performed on an ambulatory basis. Am J Dis Child 1987, 141:1266-1270.
56. Markowitz M.E., Rosen J.F. Need for the lead mobilization test in children with lead poisoning. J Pediatr 1991, 119:305-310.
57. Saenger P., Rosen J.F., Markowitz M. Diagnostic significance of edetate disodium calcium testing in children with increased lead absorption. Am J Dis Child 1982, 136:312-315.
58. 2EDTA provocative test. J Pediatr 1984, 104:337-341.
59. Sokas R.K., Atleson J., Keogh J.P. Shortened forms of provocative lead chelation. J Occup Med 1988, 30:420-424.
60. Haust H.L., Ali H., Haines D.S., et al. Short-term administration of dimercaptopropanol (BAL) and calcium disodium edetate (EDTA) for diagnostic and therapeutic lead mobilization. Int J Biochem 1980, 12:897-904.
61. Chisolm J.J. Mobilization of lead by calcium disodium edetate. A reappraisal. Am J Dis Child 1987, 141:1256-1257.
62. 2EDTA) chelation in moderate childhood lead poisoning. Pediatrics 1993, 92:265-271.
63. Jugo S., Maliković T., Kostial K. Influence of chelating agents on the gastrointestinal absorption of lead. Toxicol Appl Pharmacol 1975, 34:259-263.
64. Chia K.S., Tan A.L., Chia S.E., et al. Renal tubular function of cadmium exposed workers. Ann Acad Med Singapore 1992, 21:756-759.
65. Kales S.N., Goldman R.H. Mercury exposure: current concepts, controversies, and a clinic's experience. J Occup Environ Med 2002, 44:143-154.
66. Allain P., Mauras Y., Premel-Cabic A., et al. Effects of an EDTA infusion on the urinary elimination of several elements in healthy subjects. Br J Clin Pharmacol 1991, 31:347-349.
67. Allain P., Mauras Y., Krari N., et al. Plasma and urine aluminium concentrations in healthy subjects after administration of sucralfate. Br J Clin Pharmacol 1990, 29:391-395.
68. Allain P., Mauras Y., Chaleil D., et al. Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis. Br J Clin Pharmacol 1987, 24:207-212.
69. Perry H.M., Perry E.F. Normal concentrations of some trace metals in human urine: changes produced by ethylenediaminetetraacetate. J Clin Invest 1959, 38:1452-1463.
70. Frumkin H., Manning C.C., Williams P.L., et al. Diagnostic chelation challenge with DMSA: a biomarker of long-term mercury exposure?. Environ Health Perspect 2001, 109:167-171.
71. Soden S.E., Lowry J.A., Garrison C.B., et al. 24-hour provoked urine excretion test for heavy metals in children with autism and typically developing controls, a pilot study. Clin Toxicol (Phila) 2007, 45:476-481.
72. Brodkin E., Copes R., Mattman A., et al. Lead and mercury exposures: interpretation and action. CMAJ 2007, 176:59-63.
73. Risher J.F., Amler S.N. Mercury exposure: evaluation and intervention. The inappropriate use of chelating agents in the diagnosis and treatment of putative mercury poisoning. Neurotoxicology 2005, 26:691-699.
74. Charlton N., Wallace K.L. American College of Medical Toxicology position statement on post-chelator challenge urinary metal testing. J Med Toxicol 2010, 6:74-75.
75. Andersen A.H. Experimental studies on the pharmacology of activated charcoal. III: adsorption from gastro-intestinal contents. Acta Pharmacol Toxicol 1948, 4:275-284.
76. Lehmann P.A., Favari L. Parameters for the adsorption of thallium ions by activated charcoal and Prussian blue. J Toxicol Clin Toxicol 1984, 22:331-339.
77. Hoffman R.S., Stringer J.A., Feinberg R.S., et al. Comparative efficacy of thallium adsorption by activated charcoal, Prussian blue, and sodium polystyrene sulfonate. J Toxicol Clin Toxicol 1999, 37:833-837.
78. Bailly R., Lauwerys R., Buchet J.P., et al. Experimental and human studies on antimony metabolism: their relevance for the biological monitoring of workers exposed to inorganic antimony. Br J Ind Med 1991, 48:93-97.
79. Basinger M.A., Jones M.M. Structural requirements for chelate antidotal efficacy in acute antimony (III) intoxication. Res Commun Chem Pathol Pharmacol 1981, 32:355-363.
80. Zimmer L.J., Carter D.E. The efficacy of 2,3-dimercaptopropanol and d-penicillamine on methyl mercury induced neurological signs and weight loss. Life Sci 1978, 23:1025-1034.
81. Thompson R.H., Whittaker V.P. Antidotal activity of British anti-Lewisite against compounds of antimony, gold and mercury. Biochem J 1947, 41:342-346.
82. Aposhian H.V., Carter D.E., Hoover T.D., et al. DMSA, DMPS, and DMPA-as arsenic antidotes. Fundam Appl Toxicol 1984, 4:S58-S70.
83. Kreppel H., Reichl F.X., Kleine A., et al. Antidotal efficacy of newly synthesized dimercaptosuccinic acid (DMSA) monoesters in experimental arsenic poisoning in mice. Fundam Appl Toxicol 1995, 26:239-245.
84. Rogan W.J., Dietrich K.N., Ware J.H., et al. The effect of chelation therapy with succimer on neuropsychological development in children exposed to lead. N Engl J Med 2001, 344:1421-1426.
85. Baxter A.J., Krenzelok E.P. Pediatric fatality secondary to EDTA chelation. Clin Toxicol (Phila) 2008, 46(10):1083-1084.